Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 28, 2026

Have Salesforce shares hit bottom? BNP Paribas eyes catalysts to turn stock around

View original at seekingalpha.com
Have Salesforce shares hit bottom?…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Buybacks are clearly not enough to trigger new investor interest or confidence, but next week's event highlighting Slackbot may serve as a near-term catalyst as it is likely to be another step in demonstrating real-world customer adoption of Salesforce's AI products

    60% confidence
  • At 4Q results, Salesforce announced a $50bn repurchase authorization, with the first $20bn completed by 3/15, the next $5bn completed by the end of FY27e, and the final $25bn yet to be scheduled

    60% confidence
  • Salesforce stock might have finally reached its low point, and multiple near-term catalysts could help

    60% confidence
  • Total FY27 buyback estimate increases to ~$25bn from ~$16bn previously, driving an 8% reduction in diluted share count for FY27 versus prior estimate

    60% confidence

Data points we hold from this source

Salesforce · share buyback completed20 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Have Salesforce shares hit bottom? BNP Paribas eyes catalysts to turn stock around — Source | Via News | ViaNews Market